Shree Ganesh Remedies share news, announcements and annual reports
NSE: SGRLBSE: 540737Pharmaceuticals & BiotechnologySmall Cap
Share price at the NSE close on 30 Oct 2026. Previous close ₹639.75.
30 Oct: open ₹639.75, high ₹651.85, low ₹610.00
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹792 Cr1,715th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 65.44
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 4.78
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.16
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 7,62259.3% delivered
Shree Ganesh Remedies share news and announcements
464 announcements, routine notices left out, newest first. Page 5 of 10.
Jan 2023
16 Jan · Results
10 Jan · Board meeting
Meeting on 16 Jan 2023: quarterly results
Nov 2022
28 Nov · Analysts
21 Nov · Analysts
21 Nov · Related Party Transactions In Terms Of Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
18 Nov · Analysts
16 Nov · Analysts
Oct 2022
23 Oct · Results
17 Oct · Board meeting
Meeting on 23 Oct 2022: quarterly results10 Oct · Statement Of Investor Complaints For The Quarter Ended September 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 5 4 1
Sep 2022
28 Sep · Meeting
6 Sep · Corporate action
5 Sep · Reg. 34 (1) Annual Report.
Aug 2022
4 Aug · Intimation Of Receipt Of Approval For Re-Classification Of Shareholder Of Shree Ganesh Remedies Limited ('The Company') From 'Promoter And Promoter Group' Category To The 'Public' Category Under Regulations 30 And 31A Of The Securities And Exchange Board Of India (Listing Obligations Disclosure Requirements) Regulations, 2015 ('Listing Regulations').
Jul 2022
18 Jul · Intimation Of Submission Of Application For Re-Classification.
12 Jul · Management
12 Jul · Results
12 Jul · Results
9 Jul · Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 1 1 04 Jul · Board meeting
Meeting on 12 Jul 2022: quarterly results
May 2022
13 May · Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
6 May · Board meeting
Apr 2022
27 Apr · Board meeting
Meeting on 6 May 2022: audited results, final dividend and dividend18 Apr · Statement Of Investor Complaints For The Quarter Ended March 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 09 Apr · Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Acceptance Of Bid Participated For The E-Auction Of Assets Of M/S Jaiswal Pharmachem Limited.
Mar 2022
12 Mar · Results
Details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly <a href="https://www.bseindia.com/stock-share-price/meetings/voting-results/540737 ....11 Mar · Results
Feb 2022
16 Feb · Corporate Action-Intimation of Right issue
8 Feb · Meeting